Company / Net Income
Jade Biosciences, Inc. Net Income History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$69.6M
FY2024
5-year range
-$75.5M / -$9.6M
FY2020-FY2024
Trend
+7.8%
vs FY2023
Sector context
#94 of 215
Health Care
What the data says
At -$70M, Jade Biosciences, Inc.'s net income ranks #94 of 215 in the Health Care sector. Net Income returned to growth in FY2024 after 3 years of decline, reaching -$70M.
Based on SEC 10-K filings.
-$70M in FY2024.
Declined from -$52M to -$70M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#94 of 215 in Health CareTop 44% of 215This company -$69.6M Sector average $431.3M
▼
-116.1% below sector average
Key checks
Key Insights
- In FY2024, net income increased 7.8% year-over-year.
- Ranks #94 out of 215 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$69.6M | +7.8% |
| FY2023 | -$75.5M | -46.6% |
| FY2022 | -$51.5M | -124.3% |
| FY2021 | -$23.0M | -138.9% |
| FY2020 | -$9.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026